About Us

Our Vision for the Future

To Save Lives with Early Detection of Lung Cancer

At VisionGate, our mission is to save lives through the early detection and prevention of cancer. Our cutting-edge technologies are designed to accurately and quickly detect early-stage lung cancer using a simple, non-intrusive test.

You’re in
Good Hands

We’re backed by a talented team of scientists, researchers, and doctors.

With over 150 years of combined experience, our team at VisionGate has considerable knowledge in the creation of cutting-edge technologies in fields including pharmaceuticals and diagnostics.

Consisting of scientists, researchers, and doctors with backgrounds in a broad range of fields, we’ve put our heads together to develop world class early stage lung cancer detection methods.

visiongate team experience

Our Technology

Our breakthrough technology helps detect early signs of lung cancer that otherwise may not be discovered. Through non-intrusive testing we’re able to detect the abnormal cells indicating lung cancer and lung dysplasia.

Non-Intrusive Testing

Sputum (phlegm) samples from a deep cough (LuCED° Lung Test) are collected over a three-day period using a take-home test kit.

AI-Powered Cancer Detection

Our AI-based classification of cells can identify 1,000 cell images per second and over 800 3D cell features at a 200 nanometer isotropic resolution.

Patented Cell-CT Imaging

High-resolution 3D images (Cell-CT™) of individual cells contained in the sputum measure hundreds of disease indicators and molecular markers in each cell.

Our Partners

VisionGate has strong clinical engagement with leading academic and healthcare institutions such as Northwestern Medicine, Vrijie University (Netherlands), and Kaiser Permanente.